TraumaShield
Request a briefing
FDA-approved agent·Novel second medical use·Post-trauma intervention·Fear-memory consolidation modulation·Critical window deployment·PTSD prevention·Medical device + pharma convergence·IP protected·505(b)(2) pathway·FDA-approved agent·Novel second medical use·Post-trauma intervention·Fear-memory consolidation modulation·Critical window deployment·PTSD prevention·Medical device + pharma convergence·IP protected·505(b)(2) pathway·
Request a briefing
TraumaShield
Request a briefing
Legal

Accessibility Statement

We want everyone to be able to use this website, including people with disabilities.

Last updated: October 31, 2026

Our commitment

TraumaShield is committed to making this website accessible. We aim to conform to the Web Content Accessibility Guidelines (WCAG) 2.1 at level AA and to Israeli Standard 5568, in line with the Equal Rights for Persons with Disabilities (Service Accessibility Adjustments) Regulations, 5773-2013.

What we have done

  • Semantic page structure with clear headings and landmarks.
  • Text alternatives for meaningful images.
  • Full keyboard navigation with visible focus indicators.
  • Color contrast designed to meet WCAG AA for body text.
  • All content is readable without JavaScript.
  • Animations respect the reduced-motion setting of your device.
  • Responsive layouts that work with browser zoom and on mobile devices.

Known limitations

Some diagrams and infographics contain text within images; the key information is also provided in the surrounding text. We continue to review the site and fix issues as we find them. This statement was last reviewed on October 31, 2026.

Feedback and assistance

If you encounter an accessibility barrier or need information in another format, please contact our accessibility coordinator, David Slobodiansky, by email at david@traumashield.co or by phone at +972-54-200-3244. Please describe the page and the problem, and we will respond as soon as possible.

Company details

TraumaShield LTD., Nir Am 7915500, Israel.